文献速递骨软组织肉瘤与黑色素瘤

大分割三周术前放疗用于软组织肉瘤患者(HYPORT-STS):单中心、开放标签、单臂2期试验

Hypofractionated, 3-week, preoperative radiotherapy for patients with soft tissue sarcomas (HYPORT-STS): a single-centre, open-label, single-arm, phase 2 trial.
PubMed 文献 · Lancet Oncol · 2022-11-04

HYPORT-STS是一项单中心、开放标签、单臂2期试验,纳入120例非转移性四肢或浅表躯干软组织肉瘤成人患者,接受42.75 Gy/15次/3周术前放疗。术后120天内37例(31%,95%CI 24-40)发生主要伤口并发症,中位发生时间37天,未出现≥3级急性放疗毒性或治疗中严重不良事件,无治疗相关死亡。作者认为该方案安全,可作为更方便的替代选择,长期肿瘤学、晚期毒性和功能结局结果待报告。

要点

  • 120例软组织肉瘤患者接受42.75 Gy/15次/3周术前放疗,术后120天内主要伤口并发症发生率为31%(95%CI 24-40)。
  • 未出现≥3级急性放疗毒性或治疗中严重不良事件,无治疗相关死亡。
  • 115例中4例(3%)出现≥3级晚期放疗毒性:股骨骨折2例、淋巴水肿1例、皮肤溃疡1例。

核心结论

  • 中度大分割术前放疗用于软组织肉瘤患者是安全的,因此可能成为比常规分割放疗更方便的替代方案。
  • 可将这些结果告知患者,并可能提供该方案,尤其当有助于在肉瘤专科中心接受治疗时。
  • 长期肿瘤学、晚期毒性和功能结局结果有待报告。

研究设计与样本

  • 单中心、开放标签、单臂2期试验(HYPORT-STS),在美国德克萨斯州休斯顿MD Anderson癌症中心进行。
  • 2018年12月18日至2021年1月6日评估157例患者资格,其中120例入组并接受大分割术前放疗。
  • 入组标准为年龄≥18岁、非转移性四肢或浅表躯干软组织肉瘤、ECOG体能状态0-3分。
  • 干预为术前放疗42.75 Gy分15次、每次2.85 Gy/天、共3周(每周5次)。
  • 主要终点为术后120天内发生的主要伤口并发症,安全性分析纳入所有入组患者。

主要发现

  • 120例患者中37例(31%,95%CI 24-40)在术后中位37天(IQR 25-59)发生主要伤口并发症。
  • 无患者出现≥3级急性放疗毒性(放疗期间或放疗结束后4周内,CTCAE 4.0版)或治疗中严重不良事件。
  • 115例患者中4例(3%)出现至少≥3级晚期放疗毒性(术后≥6个月):股骨骨折2例、淋巴水肿1例、皮肤溃疡1例。
  • 无治疗相关死亡。
  • 术后中位随访24个月(IQR 17-30),停止规则计算在任何时点均未提示因缺乏安全性而应提前终止试验。

关键数值与推荐

  • 主要伤口并发症定义为需在全身或区域麻醉下二次手术处理伤口、因伤口护理再入院、有创操作处理伤口、对至少2 cm长的伤口区域进行深部填塞、延长换药、为修正刃厚皮片而再次手术、或湿敷超过4周。
  • 安全性监测采用贝叶斯单臂时间-事件停止规则模拟器,将研究参与者术后120天主要伤口并发症发生率与历史发生率35%进行比较。
  • 晚期放疗毒性采用CTCAE或RTOG/EORTC晚期放射损伤评分方案评估。

临床怎么用

  • 作者认为中度大分割术前放疗是安全的,可能成为比常规分割放疗更方便的替代方案。
  • 作者建议可将这些结果告知患者,并可能提供该方案,尤其当有助于在肉瘤专科中心接受治疗时。
  • 原文未据此给出其他临床推荐。

局限性

  • 单中心、开放标签、单臂设计。
  • 长期肿瘤学、晚期毒性和功能结局结果有待报告。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The standard preoperative radiotherapy regimen of 50 Gy delivered in 25 fractions for 5 weeks for soft tissue sarcomas results in excellent local control, with major wound complications occurring in approximately 35% of patients. We aimed to investigate the safety of a moderately hypofractionated, shorter regimen of radiotherapy, which could be more convenient for patients. METHODS: This single-centre, open-label, single-arm, phase 2 trial (HYPORT-STS) was done at a single tertiary cancer care centre (MD Anderson Cancer Center, Houston, TX, USA). We administered preoperative radiotherapy to a dose of 42·75 Gy in 15 fractions of 2·85 Gy/day for 3 weeks (five fractions per week) to adults (aged ≥18 years) with non-metastatic soft tissue sarcomas of the extremities or superficial trunk and an Eastern Cooperative Oncology Group performance status of 0-3. The primary endpoint was a major wound complication occurring within 120 days of surgery. Major wound complications were defined as those requiring a secondary operation, or operations, under general or regional anaesthesia for wound treatment; readmission to the hospital for wound care; invasive procedures for wound care; deep wound packing to an area of wound measuring at least 2 cm in length; prolonged dressing changes; repeat surgery for revision of a split thickness skin graft; or wet dressings for longer than 4 weeks. We analysed our primary outcome and safety in all patients who enrolled. We monitored safety using a Bayesian, one-arm, time-to-event stopping rule simulator comparing the rate of major wound complications at 120 days post-surgery among study participants with the historical rate of 35%. This trial is registered with ClinicalTrials.gov, NCT03819985, recruitment is complete, and follow-up continues. FINDINGS: Between Dec 18, 2018, and Jan 6, 2021, we assessed 157 patients for eligibility, of whom 120 were enrolled and received hypofractionated preoperative radiotherapy. At no time did the stopping rule computation indicate that the trial should be stopped early for lack of safety. Median postoperative follow-up was 24 months (IQR 17-30). Of 120 patients, 37 (31%, 95% CI 24-40) developed a major wound complication at a median time of 37 days (IQR 25-59) after surgery. No patient had acute radiation toxicity (during radiotherapy or within 4 weeks of the radiotherapy end date) of grade 3 or worse (Common Terminology Criteria for Adverse Events [CTCAE] version 4.0) or an on-treatment serious adverse event. Four (3%) of 115 patients had late radiation toxicity (≥6 months post-surgery) of at least grade 3 (CTCAE or Radiation Therapy Oncology Group/European Organisation for Research and Treatment of Cancer Late Radiation Morbidity Scoring Scheme): femur fractures (n=2), lymphoedema (n=1), and skin ulceration (n=1). There were no treatment-related deaths. INTERPRETATION: Moderately hypofractionated preoperative radiotherapy delivered to patients with soft tissue sarcomas was safe and could therefore be a more convenient alternative to conventionally fractionated radiotherapy. Patients can be counselled about these results and potentially offered this regimen, particularly if it facilitates care at a sarcoma specialty centre. Results on long-term oncological, late toxicity, and functional outcomes are awaited. FUNDING: The National Cancer Institute.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Guadagnolo BA, Bassett RL, Mitra D, et al. Hypofractionated, 3-week, preoperative radiotherapy for patients with soft tissue sarcomas (HYPORT-STS): a single-centre, open-label, single-arm, phase 2 trial. Lancet Oncol. 2022. PMID: 36343656. doi:10.1016/S1470-2045(22)00638-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。